Pediatric neurofibromatosis type 2: clinical and molecular presentation, management of vestibular schwannomas, and hearing rehabilitation

被引:0
|
作者
Nicolas -Xavier Bonne
Rabih Aboukais
Marc Baroncini
Audrey Hochart
Pierre Leblond
Franck Broly
Frédérique Dubrulle
Jean-Paul Lejeune
Christophe Vincent
机构
[1] CHRU de Lille,Department of Otology and Neurotology
[2] CHRU de Lille,Department of Neurosurgery
[3] Centre Oscar Lambret,Department of Pediatric Oncology
[4] CHRU de Lille,Department of Genetic
[5] CHRU Lille,Service de Toxicologie, Génopathies
[6] CHRU Lille,Department of Radiology, Hôpital Huriez
来源
Child's Nervous System | 2016年 / 32卷
关键词
Neurofibromatosis type 2; Vestibular schwannoma; Middle fossa; Hearing préservation; Auditory brainstem implant;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2403 / 2413
页数:10
相关论文
共 50 条
  • [42] Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas
    Blakeley, Jaishri O.
    Ye, Xiaobu
    Duda, Dan G.
    Halpin, Chris F.
    Bergner, Amanda L.
    Muzikansky, Alona
    Merker, Vanessa L.
    Gerstner, Elizabeth R.
    Fayad, Laura M.
    Ahlawat, Shivani
    Jacobs, Michael A.
    Jain, Rakesh K.
    Zalewski, Christopher
    Dombi, Eva
    Widemann, Brigitte C.
    Plotkin, Scott R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (14) : 1669 - U220
  • [43] Surgical treatment of large vestibular schwannomas in patients with neurofibromatosis type 2: outcomes on facial nerve function and hearing preservation
    Fu Zhao
    Bo Wang
    Zhijun Yang
    Qiangyi Zhou
    Peng Li
    Xingchao Wang
    Jing Zhang
    Junting Zhang
    Pinan Liu
    Journal of Neuro-Oncology, 2018, 138 : 417 - 424
  • [44] Hearing preservation surgery for neurofibromatosis type 2-related vestibular schwannoma in pediatric patients
    Slattery, William H., III
    Fisher, Laurel M.
    Hitselberger, William
    Friedman, Rick A.
    Brackmann, Derald E.
    JOURNAL OF NEUROSURGERY, 2007, 106 (04) : 255 - 260
  • [45] Microsurgery for patients diagnosed with neurofibromatosis type 2 complicated by vestibular schwannomas: Clinical experience and strategy for treatments
    Chen, Li-Hua
    Zhang, Hong-Tian
    Xu, Ru-Xiang
    Zhang, Li
    Li, Wen-De
    Sun, Kai
    MEDICINE, 2018, 97 (17)
  • [46] Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: An analysis of tumor control, complications, and hearing preservation rates
    Mathieu, David
    Kondziolka, Douglas
    Flickinger, John C.
    Niranjan, Ajay
    Williamson, Richard
    Martin, Juan J.
    Dade Lunsford, L.
    NEUROSURGERY, 2007, 60 (03) : 460 - 468
  • [47] Surgical treatment of large vestibular schwannomas in patients with neurofibromatosis type 2: outcomes on facial nerve function and hearing preservation
    Zhao, Fu
    Wang, Bo
    Yang, Zhijun
    Zhou, Qiangyi
    Li, Peng
    Wang, Xingchao
    Zhang, Jing
    Zhang, Junting
    Liu, Pinan
    JOURNAL OF NEURO-ONCOLOGY, 2018, 138 (02) : 417 - 424
  • [48] Age at Onset and Presenting Symptoms of Neurofibromatosis Type 2 as Prognostic Factors for Clinical Course of Vestibular Schwannomas
    Gugel, Isabel
    Grimm, Florian
    Zipfel, Julian
    Teuber, Christian
    Ernemann, Ulrike
    Kluwe, Lan
    Tatagiba, Marcos
    Mautner, Victor-Felix
    Schuhmann, Martin Ulrich
    CANCERS, 2020, 12 (09) : 1 - 12
  • [49] Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas
    Kluwe, L
    Mautner, V
    Heinrich, B
    Dezube, R
    Jacoby, LB
    Friedrich, RE
    MacCollin, M
    JOURNAL OF MEDICAL GENETICS, 2003, 40 (02) : 109 - 114
  • [50] Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2
    Said Farschtschi
    Philipp Kollmann
    Carsten Dalchow
    Alexander Stein
    Victor-Felix Mautner
    European Archives of Oto-Rhino-Laryngology, 2015, 272 : 3857 - 3860